Top Qs
Timeline
Chat
Perspective
Mavoglurant
Chemical compound From Wikipedia, the free encyclopedia
Remove ads
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions.[1][2] It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5).[3][4][5]
Mavoglurant was under development by Novartis and reached phase II and phase III clinical trials.[2][6] Phase IIb/III dose finding and evaluation trials for fragile X-syndrome were discontinued by the end of 2014.[7] Otherwise, it would have been the first drug to treat the underlying disorder instead of the symptoms of fragile X syndrome.[8] Mavoglurant was also in phase II clinical trials for Levodopa-induced dyskinesia.[9][10] In 2007, Norvartis had conducted a clinical study to assess its ability of reducing cigarette smoking, but no results had been published up till now.[11] Novartis was conducting a clinical trial with this drug on obsessive–compulsive disorder.[12]
Novartis discontinued development of mavoglurant for fragile X syndrome in April 2014 following disappointing trial results.[7] Development was discontinued for other indications by 2017.[1]
Recently, Stalicla, a biotech company applying artificial intelligence to identify subgroups of high-responder patients, acquired worldwide rights from Novartis to progress the drug for substance-use and neurodevelopmental disorders.[13][14][15]
Remove ads
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads